Polypills for HFrEF are being tested in RCTs, and if they’re approved, experts want to be ready for their rollout and use.

There’s a need in secondary prevention for personalized risk estimates to motivate patients and guide care, researchers say.

Researchers support limiting these surgeries to centers that do the most cases, though true high-volume hospitals remain rare ...